Synthetic Biologics Inc (SYN) Short Interest Down 57.6% in October

Share on StockTwits

Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 278,160 shares, a drop of 57.6% from the October 15th total of 655,659 shares. Currently, 9.3% of the company’s stock are short sold. Based on an average trading volume of 412,730 shares, the days-to-cover ratio is presently 0.7 days.

Several equities analysts have commented on SYN shares. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Synthetic Biologics in a research report on Thursday, August 9th.

Shares of Synthetic Biologics stock traded down $0.07 during mid-day trading on Friday, hitting $0.84. 322,921 shares of the stock were exchanged, compared to its average volume of 315,270. Synthetic Biologics has a 12 month low of $0.77 and a 12 month high of $26.60.

Synthetic Biologics (NYSEAMERICAN:SYN) last posted its earnings results on Thursday, November 8th. The company reported ($0.93) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.39.

COPYRIGHT VIOLATION WARNING: This article was posted by Macon Daily and is the property of of Macon Daily. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://macondaily.com/2018/11/09/synthetic-biologics-inc-syn-short-interest-down-57-6-in-october.html.

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Featured Article: Yield Curve

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply